Latest Headlines

  1. Harbour BioMed And Evinova China Announce Strategic AI Collaboration To Accelerate AI-Enabled Drug Development 11/7/2025

    Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Evinova, a global health-tech company accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, announced a strategic collaboration in artificial intelligence (AI).

  2. Abzena And Mabqi Announce Strategic Partnership To Offer Integrated Discovery Through Development Solution 11/6/2025

    This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution.

  3. MavriX Bio Announces First Patient Dosed In ASCEND-AS Trial Of MVX-220, Investigational Gene Therapy For Angelman Syndrome 11/6/2025

    MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the first patient has been dosed in the Phase 1/2 ASCEND-AS clinical trial of MVX-220, an investigational gene therapy for AS.

  4. Arcturis And Royal Berkshire NHS Foundation Trust Enter Strategic Partnership 11/5/2025

    Arcturis, the UK leader in the curation of deep, multi-modal data to support the development of precision medicines, announces the continuing expansion of its Real-World Data Network (”RWD Network”) through the signing of a multi-year strategic partnership with Royal Berkshire NHS Foundation Trust (“Royal Berkshire”).

  5. NanoTemper Strengthens Biopharma Discovery Portfolio With Acquisition Of Envue Technologies And Launch of Dianthus™ α 11/5/2025

    NanoTemper Technologies, a leading provider of high-precision biophysical analysis tools, today announced its acquisition of Envue Technologies, a Swedish startup pioneering Nanofluidic Scattering Microscopy (NSM).

  6. Tenpoint Therapeutics Ltd. Announces Submission Of A New Drug Application For BRIMOCHOL PF For The Treatment Of Presbyopia To The MFDS In South Korea 11/5/2025

    Tenpoint Therapeutics, Ltd., a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that its partner, Zhaoke Ophthalmology Ltd. (“Zhaoke Ophthalmology”), a leading ophthalmic pharmaceutical company, has supported its South Korean partner, Kwangdong Pharmaceutical Co., Ltd. (“KDP”), in submitting a New Drug Application (NDA) for BRIMOCHOL PF to the Ministry of Food and Drug Safety (MFDS) in South Korea. KDP will be responsible for the manufacturing and distribution of BRIMOCHOL PF in South Korea.

  7. U.S. FDA Grants Orphan Drug Designation To Leukogene Therapeutics' M2T-CD33 (LTI-214) For The Treatment Of Acute Myeloid Leukemia 11/5/2025

    Leukogene Therapeutics Inc. (LTI), a biopharmaceutical company developing next-generation immunotherapies for hematologic and other malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s lead product candidate, M2T-CD33 (LTI-214), for the treatment of Acute Myeloid Leukemia (AML).

  8. MIT Researchers Invent New Human Brain Model To Enable Disease Research, Drug Discovery 11/5/2025

    A new 3D human brain tissue platform developed by MIT researchers is the first to integrate all major brain cell types, including neurons, glial cells, and the vasculature, into a single culture. 

  9. Calico Life Sciences Announces U.S. FDA Orphan Drug Designation For Investigational Treatment Of Autosomal Dominant Polycystic Kidney Disease 11/5/2025

    Calico Life Sciences LLC (Calico), a biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D. Levinson, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABBV-CLS-628, an investigational therapy for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

  10. Sanyou Bio And Shanghai ZJ Bio-Tech Sign Strategic Cooperation Agreement On Automated Development Of Innovative Biologics To Jointly Tackle R&D Bottlenecks And Provide New Momentum For Innovative Drug R&D 11/3/2025

    Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Shanghai ZJ Bio-Tech technology Co., Ltd. (hereinafter referred to as "Shanghai ZJ Bio-Tech") jointly announced the official signing of a strategic cooperation agreement on the automated development of innovative biologics.